Table 3:
Log10-normalised percentage of peripheral blood plasma ASC specks by classes of somatic gene mutations in patients with myelodysplastic syndromes
| n | Mean (SD) | Median (IQR) | p value | |
|---|---|---|---|---|
| Splicing gene mutations* | ||||
| Yes | 78 | −0·25 (0·61) | −0·35 (−0·62 to 0·07) |
0·026 |
| No | 18 | −0·54 (0·44) | −0·52 (−0·80 to −0·24) |
·· |
| Methylation gene mutations† | ||||
| Yes | 52 | −0·20 (0·69) | −0·32 (−0·61 to 0·11) |
0·039 |
| No | 44 | −0·44 (0·43) | −0·42 (−0·75 to −0·13) |
·· |
| Transcriptional gene mutations‡ | ||||
| Yes | 37 | −0·29 (0·66) | −0·34 (−0·62 to 0·08) |
0·821 |
| No | 59 | −0·32 (0·56) | −0·40 (−0·70 to −0·04) |
·· |
| Signalling gene mutations§ | ||||
| Yes | 11 | −0·26 (0·66) | −0·44 (−0·79 to −0·11) |
0·787 |
| No | 85 | −0·31 (0·59) | −0·36 (−0·67 to 0·03) |
·· |
| ≥1 mutations | ||||
| Yes | 92 | −0·28 (0·59) | −0·35 (−0·63 to 0·03) |
0·024 |
| No | 4 | −0·90 (0·32) | −0·86 (−1·08 to −0·67) |
·· |
| ≥2 mutations | ||||
| Yes | 68 | −0·22 (0·63) | −0·32 (−0·60 to −0·11) |
0·008 |
| No | 28 | −0·53 (0·44) | −0·50 (−0·85 to −0·31) |
·· |
| Total number of mutations | ||||
| 0 | 4 | −0·90 (0·32) | −0·86 (−1·08 to −0·67) |
0·207 |
| 1 | 26 | −0·45 (0·43) | −0·44 (−0·76 to −0·12) |
·· |
| 2 | 39 | −0·23 (0·54) | −0·34 (−0·50 to 0·07) |
·· |
| 3 | 13 | −0·15 (0·60) | −0·08 (−0·62 to 0·20) |
·· |
| 4 | 11 | −0·25 (1·02) | −0·43 (−0·73 to −0·03) |
·· |
| 5 | 3 | −0·17 (0·30) | −0·24 (−0·34 to −0·04) |
·· |
ASC=apoptosis-associated speck-like protein containing a CARD.
*
SF3B1, SRSF2, U2AF, or ZRSR2 mutations.
†
Tet2, IDH, DNMT3A, ASXL1, or EZH2 mutations.
‡
SetBP1, TP53, PHF6, RUNX1, ETV6, or NPM1 mutations.
§
CBL, NRAS, KIT, JAK2, or MPL mutations.